相关临床试验
916
105 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
70
7.6%
已完成
474
51.8%
Enrolling By Invitation
6
0.7%
尚未招募
29
3.2%
招募中
154
16.8%
暂停
4
0.4%
终止
111
12.1%
Unknown
5
0.6%
撤回
63
6.9%
暂无批准数据
- The American Cancer Society plans to build Hope Lodge Chicago at 5700 S. Stony Island Ave., providing free lodging for cancer patients and caregivers traveling for treatment. - UChicago Medicine serves as the primary partner, with the University of Chicago providing the property via long-term lease and contributing construction funds. - The facility will sit about one mile from the new AbbVie Foundation Cancer Pavilion, a 575,000-square-foot cancer center opening in April 2027. - Hope Lodge communities nationwide already serve more than 36,000 patients and caregivers annually, saving over $85 million in lodging costs each year.
- A Phase 1 trial found that six of 15 participants with peanut allergy achieved improved tolerance after receiving fecal microbiome transplant capsules, with effects lasting up to four months. - Before treatment, participants could not tolerate more than 100 mg of peanut protein; afterward, five could consume 600 mg or more—equivalent to about two and a half peanuts. - Experts highlight the sustained benefit as particularly exciting, contrasting it with current therapies whose effects wane without continued treatment and exposure. - Mouse studies using participant stool samples suggest the approach may work for food allergies beyond peanuts, with responder-derived bacteria protecting mice from egg protein allergy.
- Insilico Medicine, collaborating with University of Chicago and Johns Hopkins University, published the first comprehensive molecular characterization of IP-SNSCC in npj Precision Oncology. - The study integrated whole-exome sequencing, RNA sequencing, mitochondrial DNA sequencing, and AI-driven target prioritization to reconstruct the molecular evolution of this rare cancer. - PandaOmics, Insilico's proprietary AI platform, identified both clinically actionable targets with existing FDA-approved inhibitors and novel targets for future drug discovery programs. - The research establishes a scalable AI-powered framework for accelerating drug discovery in rare diseases where small patient populations constrain traditional research models.
- A new study published in Alzheimer's Research & Therapy demonstrates that SuperAgers cannot be distinguished from cognitively average peers based on APOE or Alzheimer's polygenic risk scores. - Researchers analyzed 142 SuperAgers and 89 cognitively average older adults across five U.S. and Canadian sites, finding no increased prevalence of rare protective genetic variants among SuperAgers. - The findings reinforce that preserving cognitive health involves more than reducing Alzheimer's disease risk alone, pointing toward protective biological, behavioral, and social pathways. - The study establishes that memory decline is not inevitable, with some individuals maintaining youthful memory into their 80s and beyond through mechanisms beyond genetics.
- A phase I trial of B440, an oral Bifidobacterium-based WT1 cancer vaccine, showed tolerability and immune enhancement in 12 metastatic urothelial cancer patients, with six demonstrating WT1-specific cellular immune responses. - Three of seven patients who received pembrolizumab rechallenge after B440 treatment showed tumor shrinkage, though causality could not be established in the small, non-randomized setting. - The University of Chicago received a $1.75 million NCI R01 award to develop engineered Bifidobacterium longum as a systemic delivery vehicle for IL-2 immunotherapy targeting metastatic pancreatic ductal adenocarcinoma. - Both approaches leverage Bifidobacterium's favorable safety profile as a human commensal, with the Chicago program incorporating a self-destruction gene circuit for added safety in systemic administration.
- Cures Within Reach has approved funding for five clinical trials at Chicago-based institutions testing approved therapies for new indications including Parkinson's disease, food allergies, and PTSD. - The trials focus on vulnerable populations including veterans and pediatric patients, with investigations ranging from wearable stimulation devices to chemotherapy drug repurposing. - The nonprofit has expanded its Chicago investment from one trial annually to four or five trials per year, emphasizing support for early-stage investigators affected by 2025 research funding cuts. - CWR's drug repurposing approach leverages existing approved therapies to accelerate treatment development, with the organization currently managing 52 funded trials across 39 institutions globally.
- Researchers at the University of Chicago developed lipid nanoparticles that deliver mRNA to insulin-producing beta cells, enabling them to express PD-L1 protein for immune protection. - The nanoparticle system successfully delayed type 1 diabetes progression in mouse models and demonstrated effectiveness in both mouse and human beta cells. - Two versions were created, including one tagged with a peptide targeting GLP-1 receptors, with both showing ability to selectively target beta cells without affecting other cell types. - The approach represents a novel strategy focusing on preserving beta cells by enhancing their self-protection rather than suppressing the autoimmune response.
- Researchers identified three genetic mutations in the CPD gene that cause congenital sensorineural hearing loss in families from Turkey, affecting the production of arginine and nitric oxide signaling. - Laboratory studies demonstrated that sildenafil (Viagra) and L-arginine supplementation can restore nitric oxide levels and reduce hair cell death in the inner ear. - The findings suggest a potential therapeutic pathway for treating this rare form of genetic deafness, though experts caution against using Viagra for hearing issues without further human trials.
- ClostraBio has commercially launched its first product featuring the next-generation probiotic strain Anaerostipes caccae CLB101™ through a partnership with Designs for Health, targeting the healthcare practitioner channel. - The company has initiated a 48-subject clinical study to evaluate the safety and tolerability of CLB101™, with exploratory endpoints examining its potential to support gut health and intestinal barrier integrity. - CLB101™ is differentiated from legacy probiotics as a strict anaerobe that directly produces butyrate in the lower gut, having achieved self-affirmed GRAS status for marketing as a dietary supplement in the US.
- Sernova Biotherapeutics and Eledon Pharmaceuticals announced a collaboration to evaluate tegoprubart, an anti-CD40L antibody, in Sernova's Phase 1/2 Cell Pouch Bio-hybrid Organ clinical trial for type 1 diabetes. - Tegoprubart will replace tacrolimus in Cohort C of the trial, potentially offering superior islet cell protection with reduced toxicity compared to standard immunosuppression. - Previous study results showed three patients achieved insulin independence with tegoprubart, demonstrating islet engraftment three to five times higher than tacrolimus-based treatments. - The partnership combines Sernova's retrievable Cell Pouch technology with Evotec's stem cell-derived islet clusters and Eledon's novel immunosuppressive approach to advance a potential functional cure for type 1 diabetes.
